
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2026

KESTRA MEDICAL TECHNOLOGIES, LTD.

(Exact name of Registrant as Specified in Its Charter)

Bermuda
(State or Other Jurisdiction
of Incorporation)

001-42549
(Commission File Number)

Not Applicable
(IRS Employer
Identification No.)

3933 Lake Washington Blvd NE
Suite 200
Kirkland, Washington
(Address of Principal Executive Offices)

98033
(Zip Code)

Registrant's Telephone Number, Including Area Code: (425) 279-8002

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, par value \$1.00 per share	KMTS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Kestra Medical Technologies, Ltd. (the “Company”) 2026 annual general meeting of shareholders (the “2026 Annual Meeting”) was held on September 9, 2026. The total number of the Company’s common shares voted in person or by proxy at the 2026 Annual Meeting was 55,399,491, representing approximately 94.53% of the 58,603,121 shares that were outstanding and entitled to vote as of July 17, 2026, the record date of the 2026 Annual Meeting. Voting results for each matter submitted to a vote at the 2026 Annual Meeting are provided below.

Proposal 1 - Election of Directors

The shareholders elected each of the three persons named below to serve as Class II directors until the Company’s 2029 annual meeting of shareholders and until their successors are duly elected and qualified, with the vote totals as set forth in the table below:

Nominee	For	Against	Abstain	Broker Non-Vote
Raymond W. Cohen	37,334,685	10,779,640	34,843	7,259,323
Kevin Reilly	38,900,190	9,204,737	35,241	7,259,323
Traci S. Umberger	38,866,030	9,238,943	35,195	7,259,323

Proposal 2 - Ratification of Independent Registered Public Accounting Firm

The shareholders ratified the appointment of PricewaterhouseCoopers as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2027, with the vote totals set forth in the table below:

For	Against	Abstain
55,356,225	8,469	34,797

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Kestra Medical Technologies, Ltd.

Date: September 10, 2026

By: /s/ Brian Webster

Name: Brian Webster

Title: President and Chief Executive Officer
